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Molecular mechanism of SHP2 activation  
by PD-1 stimulation
M. Marasco1, A. Berteotti2,3, J. Weyershaeuser4,5, N. Thorausch4,5, J. Sikorska6, J. Krausze1, 
H. J. Brandt4,5, J. Kirkpatrick1,6, P. Rios3,4,5, W. W. Schamel4,5,7, M. Köhn3,4,5*, T. Carlomagno1,2,6*
In cancer, the programmed death-1 (PD-1) pathway suppresses T cell stimulation and mediates immune escape. 
Upon stimulation, PD-1 becomes phosphorylated at its immune receptor tyrosine–based inhibitory motif (ITIM) 
and immune receptor tyrosine–based switch motif (ITSM), which then bind the Src homology 2 (SH2) domains of 
SH2-containing phosphatase 2 (SHP2), initiating T cell inactivation. The SHP2–PD-1 complex structure and the exact 
functions of the two SH2 domains and phosphorylated motifs remain unknown. Here, we explain the structural 
basis and provide functional evidence for the mechanism of PD-1-mediated SHP2 activation. We demonstrate that 
full activation is obtained only upon phosphorylation of both ITIM and ITSM: ITSM binds C-SH2 with strong affinity, 
recruiting SHP2 to PD-1, while ITIM binds N-SH2, displacing it from the catalytic pocket and activating SHP2. This 
binding event requires the formation of a new inter-domain interface, offering opportunities for the development 
of novel immunotherapeutic approaches.
INTRODUCTION
In signal transduction, cytoskeletal remodeling, cell survival, and cell 
proliferation, phosphorylation and dephosphorylation of tyrosine resi-
dues are major regulators of protein activity. The addition and removal 
of phosphate groups from the aromatic ring of tyrosine residues are 
catalyzed by protein tyrosine kinases and protein tyrosine phosphatases 
(PTPs), respectively. Among the PTPs, the cytoplasmic Src homology 2 
(SH2) domain–containing phosphatase 2 (SHP2), encoded by the 
gene ptpn11, acts as a positive transducer of proliferative and anti-
apoptotic signals from receptor tyrosine kinases, in the context of 
the Ras/mitogen-activated protein kinase (MAPK) pathway (1).
SHP2 is composed of three folded domains and a C-terminal tail 
(Fig. 1A). The N-terminal SH2 (N-SH2) and C-terminal SH2 (C-SH2) 
domains bind phosphopeptides, thereby modulating the phosphatase 
activity (2). The PTP domain harbors the catalytic functionality in 
the conserved signature motif HCX5R, which contains the catalytic 
cysteine. The disordered C-terminal tail contains two potential 
phosphorylation sites (Y542 and Y584) and has a putative regulatory 
function (3).
SHP2 has been found to adopt an autoinhibited, catalytically in-
active conformation, in which the DE loop of the N-SH2 domain 
occludes the active site of the PTP domain (fig. S1A) (2). Con-
sequently, phosphotyrosine (pY)–bearing peptides binding to N-SH2 
have been proposed to activate SHP2 by inducing a conformational 
change that disrupts the N-SH2–PTP interaction (2). Bidentate 
phosphopeptides, which contain two pY residues and can potentially 
bind to both N-SH2 and C-SH2 domains simultaneously, are stronger 
activators than phosphopeptides with a single pY site (4); however, 
mutational analysis has demonstrated that binding of phosphopeptides 
to N-SH2, but not to C-SH2, is essential for activation in vitro (3). 
Overall, the exact roles of the two SH2 domains in SHP2 activation 
remain unclear.
Ptpn11 has been reported to be both a proto-oncogene and a 
tumor suppressor in different cellular contexts (5). SHP2 mutations 
are associated with Noonan and LEOPARD syndromes as well as 
sporadic juvenile myelomonocytic leukemia (6–8) and have been 
implicated in breast and gastric cancers (9, 10). Consequently, SHP2 
is considered a potential target for anticancer therapy (11, 12), with 
two phase 1 clinical trials currently underway (13). Besides its function 
as a positive regulator of Ras/MAPK signaling, SHP2 is a key down-
stream effector of the immune checkpoint receptor programmed 
death-1 (PD-1) in T cells (14). Once stimulated by its natural ligands 
PD-L1 or PD-L2, PD-1 is phosphorylated by Src kinases at two 
tyrosine-containing motifs, located in its cytoplasmic tail (15). The 
two motifs, termed immune receptor tyrosine–based inhibitory 
motif (ITIM) and immune receptor tyrosine–based switch motif 
(ITSM), recruit and activate SHP2, which then removes phosphate 
groups from nearby effector proteins (16). Ultimately, this leads to 
a reduction of both cytokine production and T cell proliferation, 
which results in the suppression of T cell–mediated immune response. 
The atomic details of the interaction between PD-1 and SHP2 are 
still unknown, with conflicting literature data indicating that ITIM 
is either involved (16–18) or not involved (15, 19) in SHP2 recruit-
ment or activation.
The success of anticancer therapy based on monoclonal antibodies 
that disrupt PD-1 signaling (nivolumab and pembrolizumab), 
currently approved for the treatment of metastatic melanoma, non–
small cell lung cancer, and renal cancer (20, 21), suggests that block-
ing the SHP2–PD-1 interaction by targeting SHP2 may result in an 
efficient and fairly inexpensive anticancer strategy. This hypothesis 
is supported by many reports demonstrating the role of SHP2 in 
T cell activation (14–16, 18, 19).
In this study, we elucidate the mechanism of PD-1–mediated 
SHP2 activation using a combination of biochemical, structural, 
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and cellular biology approaches. We find that phosphorylated ITIM 
and ITSM bind the N-SH2 and C-SH2 domains with distinct affin-
ities and rationalize the binding specificity by solving the structures 
of the C-SH2–ITSM, N-SH2–ITIM, and N-SH2–ITSM complexes. 
We demonstrate that a bidentate peptide, containing both ITIM 
and ITSM, activates SHP2 much more efficiently than either motif 
in isolation, implying simultaneous binding of ITIM and ITSM to 
the two SH2 domains. In agreement with this result, we find that, in 
cells, both motifs are necessary for full activation. Our structural 
data reveal that the concurrent binding of the two phosphorylated 
sites of the bidentate peptide to SHP21–220 (containing both SH2 
domains) occurs at low concentrations in a specific register, with 
ITIM binding to N-SH2 and ITSM binding to C-SH2. The formation 
of the 1:1 complex between the bidentate peptide and SHP21–220 
requires a conformational change of the protein, which alters the 
N-SH2:C-SH2 interface and may represent a way to regulate SHP2 
activation.
RESULTS
PD-1 ITSM and ITIM interact with both N-SH2 and C-SH2 
domains of SHP2
We used nuclear magnetic resonance (NMR) spectroscopy to test 
whether both pY motifs of PD-1 are able to bind the isolated N-SH2 
(SHP21–105) and C-SH2 (SHP2106–220) domains of SHP2 in vitro 
(see Fig. 1A for domain numbering). We assigned the backbone 
resonances of the N-SH2 and C-SH2 domains and monitored the 
chemical shift perturbations (CSPs) observed in two-dimensional 
(2D) 1H-15N spectra upon addition of either ITIM (FSVDpYGELDFQ) 
or ITSM (EQTEpYATIVFP) peptides (Fig. 1 and fig. S2). In the 
following text, ITIM and ITSM always indicate the phosphorylated 
form of the motifs, unless stated otherwise. ITSM binds the N-SH2 
and C-SH2 domains with dissociation constant (Kd) values in the 
high nanomolar range or lower, as indicated by the behavior of the 
NMR peaks during titration (slow-to-intermediate exchange regime; 
Fig. 1 and fig. S2). Accordingly, isothermal titration calorimetry 
(ITC) reported Kd values of 13 and 167 nM for ITSM in complex 
with C-SH2 and N-SH2, respectively. In contrast, upon addition 
of ITIM, the behavior of the 1H-15N peaks was consistent with Kd 
values in the micromolar range (intermediate-to-fast exchange 
regime). ITC data confirmed that ITIM binds N-SH2 and C-SH2 
with Kd values of 1.9 and 26.4 M, respectively. Thus, ITSM has the 
higher affinity for both SH2 domains with a 10-fold preference for 
C-SH2; conversely, ITIM displays a 10-fold preference for N-SH2. 
The CSPs induced by binding of ITIM and ITSM are in agree-
ment with the canonical binding mode of phosphopeptides to SH2 
domains (fig. S2) (22). The nonphosphorylated form of ITIM does not 
bind either of the domains, while the affinity of nonphosphorylated 
ITSM is greatly reduced with respect to the phosphorylated form 
(fig. S3).
Structures of N-SH2 and C-SH2 domains in complex 
with ITIM and ITSM
To understand the structural basis for the preferential binding of ITIM 
and ITSM to either N-SH2 or C-SH2, we determined the structure of 
the complexes. We used x-ray crystallography to solve the structures 
of the N-SH2–ITIM and N-SH2–ITSM complexes [Protein Data Bank 
(PDB) entries 6ROY and 6ROZ, respectively; Fig. 2 and table S1] 
and NMR spectroscopy for the C-SH2–ITSM complex (PDB entry 
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Fig. 1. Interaction of the N-SH2 and C-SH2 domains with ITIM and ITSM. (A) Domain composition of SHP2 and PD-1. Highlighted are the conserved R32 and R138 
required for binding phosphopeptides, the catalytic C459, and the putative phosphorylation sites Y542 and Y584 on SHP2, as well as the phosphorylation sites on the 
PD-1 cytoplasmic domain. (B and C) Excerpts from 1H-15N heteronuclear single-quantum coherence (HSQC) spectra of N-SH2 upon addition of ITIM (B) and ITSM (C). ppm, 
parts per million. (D and E) Excerpts from 1H-15N HSQC spectra of C-SH2 upon addition of ITIM (D) and ITSM (E). The protein concentration was 200 M; the color code (top) 
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In all structures, both ITIM and ITSM adopt the typical extended 
conformation observed for other phosphopeptides bound to SH2 
domains (22), with the peptide backbone arranged perpendicularly 
to the central  sheet bundle. The pY moiety is held in place by a 
network of hydrogen bonds to R32, S34, S36, and T42 of N-SH2 
or R138, S140, and S142 of C-SH2. A patch of hydrophobic amino 
acids provides an interaction surface for the nonpolar C-terminal 
part of ITSM: In C-SH2–ITSM, residues V170, V181, M202, and 
L210 surround the ITSM A(+1)–F(+5) stretch; analogously, in 
N-SH2–ITSM, the peptide C-terminal stretch is in contact with I54, 
L65, and L88. The packing of the peptide is tighter in C-SH2–ITSM 
than in N-SH2–ITSM, and C-SH2–ITSM contains two hydrogen 
bonds from the backbone HN and the side-chain hydroxyl of 
ITSM-T(+2) to the side-chain carbonyl of C-SH2–E204, which 
are absent in N-SH2–ITSM (Fig. 2). These differences result in 
the higher affinity of ITSM for C-SH2 as compared to N-SH2. Con-
versely, comparison of the x-ray structures of N-SH2–ITSM and 
N-SH2–ITIM (Fig. 2) does not explain why N-SH2 binds ITSM 
more strongly than ITIM, suggesting that the difference between 
the free energies of the complexes might be due principally to 
entropic contributions.
Comparison of the structures of the unbound (PDB entry 2SHP) 
(23) and peptide-bound N-SH2 domain shows that the BG and EF 
loops undergo large conformational changes that are necessary to 
accommodate the C-terminal part of the phosphopeptide (fig. S4). 
It has been previously reported that the conformational change of 
the EF loop induced by peptide binding is not compatible with the 
autoinhibited conformation of SHP2 (23), thus providing an expla-
nation as to how singly phosphorylated peptides activate SHP2 by 
binding to the N-SH2 domain and preventing its interaction with 
the PTP active site (fig. S1, C and D).
Activation of SHP2 by a peptide containing both ITIM 
and ITSM
Next, we tested the activation of SHP2 in the presence of ITIM and 
ITSM, as well as with the bidentate peptide ITIM-[dPEG4]2-ITSM, 
which contains both ITIM and ITSM joined by a polyethylenglycol- 
based linker. The length of the linker was chosen to mimic that of an 
extended chain of the 14 amino acids that separate ITIM and ITSM 
in the PD-1 tail, following the strategy proposed by Chen et al. (24). 
We tested the effect of these peptides on the catalytic activity of SHP2 by 
an in vitro phosphatase assay, which monitors the conversion of the 
substrate 6,8-difluoro-4-methylumbelliferone phosphate (DiFMUP) 
into the fluorescent product 6,8-difluoro-4-methylumbelliferone.
We observed dose-dependent stimulation of SHP2-dependent 
DiFMUP dephosphorylation upon addition of increasing amounts 
of ITSM and ITIM peptides, starting at concentrations of 5 and 10 M, 
respectively. Both ITSM and ITIM activated SHP2 with moderate 
potency, with ITSM producing a greater maximal response than 
ITIM (Fig. 3A). An equimolar mixture of ITIM and ITSM yielded a 
higher maximal velocity of DiFMUP dephosphorylation than either 
of the individual peptides, but also in this case, the activation of 
SHP2 was only moderate and did not reach saturation. In none of 
these assays could we determine the half-maximal stimulation con-
centration (EC50), as the response did not reach a plateau at the 
highest achievable concentrations of ITIM and ITSM.
To determine the contribution of the individual SH2 domains to 
PD-1–mediated SHP2 activation, we generated SHP2 mutants, in 
which the ability of either N-SH2 (SHP2-R32A) or C-SH2 (SHP2-
R138A) to bind phosphopeptides was disrupted. Neither the ITIM 
nor the ITSM peptide was able to activate the SHP2-R32A mutant 
(Fig. 3C), while the SHP2-R138A mutant responded to both peptides, 







































Fig. 2. Structure of SH2 domains in complex with ITIM and ITSM. (A) Crystallo-
graphic structure of N-SH2–ITIM. N-SH2, blue; ITIM, green. (B) Crystallographic 
structure of N-SH2–ITSM. N-SH2, blue; ITSM, pink. (C) Lowest energy structure of 
the NMR ensemble of C-SH2–ITSM. C-SH2, green; ITSM, pink. In each panel, an 
overview of the complete structure is shown on the left (with protein hydrophobic 
patches interacting with the peptide C-terminal region shown as gray surfaces). 
Insets on the right show the interactions of the phosphate group (top), H bonds 
formed between the peptide and the BG loop of the protein (middle), and hydro-
phobic interactions of the peptide C-terminal region (bottom). The peptide residues 
are numbered starting from the pY residue (zero) as positive and negative numbers 
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The ability of the N-SH2 domain to bind phosphopeptides is therefore 
essential for activation, while binding of phosphopeptides by both 
N-SH2 and C-SH2 is required for full activation.
The bidentate phosphorylated peptide ITIM-[dPEG4]2-ITSM 
stimulated SHP2 catalytic activity with much higher efficiency than 
either of the monophosphorylated motifs alone or in combination 
and yielded an EC50 of 39.9 ± 1.6 nM. Another bidentate peptide, 
ITSM-[dPEG4]2-ITSM, with two ITSMs, was even more potent 
than ITIM-[dPEG4]2-ITSM, with an EC50 of 3.7 ± 0.4 nM (Fig. 3A). 
Both ITIM-[dPEG4]2-ITSM and ITSM-[dPEG4]2-ITSM stimulated 
SHP2 activity up to a concentration of ~1 M, with higher peptide 
concentrations showing an inhibitory effect.
The ITIM-[dPEG4]2-ITSM bidentate peptide failed to activate 
SHP2-R32A (Fig. 3C) and displayed a weak activation profile toward 
SHP2-R138A (Fig. 3B). Overall, these data indicate that the efficacy 
of the ITIM-[dPEG4]2-ITSM peptide is strictly related to its bidentate 
functionality and requires simultaneous binding of ITIM and ITSM 
to both SH2 domains.
To rationalize the inhibition of SHP2 activity seen at high con-
centration of the bidentate peptides, we tested whether ITIM and ITSM 
are substrates of SHP2 themselves. We used a coupled enzymatic 
assay (EnzChek phosphate assay) to monitor the SHP2-dependent 
release of phosphate. As a positive control, we used a peptide derived 
from the epidermal growth factor receptor (EGFR), which is a known 
substrate of SHP2 (25). The catalytic domain of SHP2 (PTP, resi-
dues 224 to 541) dephosphorylated the ITIM, ITSM, and ITIM- 
[dPEG4]2-ITSM peptides (Fig. 3D) at high peptide concentrations 
(ranging from 25 to 400 M) and with lower efficiency compared to 
the EGFR peptide. This result indicates that the inhibition of SHP2 
activity observed in the DiFMUP activation assay at high ITIM-
[dPEG4]2-ITSM concentrations is due to substrate competition and 
suggests that the dephosphorylation of ITIM and ITSM may represent 
another layer of regulation of SHP2 activation.
Simultaneous binding of SHP21–220 to ITIM and ITSM of  
ITIM-[dPEG4]2-ITSM requires formation of a new  
interdomain interface
Next, we used 2D 1H-15N NMR spectra to monitor the binding of 
ITIM, ITSM, and ITIM-[dPEG4]2-ITSM to SHP21–220, which contains 
both SH2 domains (tandem SH2). The peak positions of unbound 
SHP21–220 matched closely with those of isolated N-SH2 and C-SH2, 
demonstrating that the two domains do not share a large interaction 
surface or substantially perturb each other’s internal structure (fig. S5A). 
In addition, the CSPs induced by either ITIM or ITSM on SHP21–220 
were very similar to those induced on isolated N-SH2 and C-SH2, 
confirming that the peptide binding sites on the two SH2 domains 
are the same in the SHP21–220 construct as in the isolated domains. 
The low affinity of ITIM for C-SH2 was apparent, as CSPs of C-SH2 
peaks upon addition of ITIM occurred only after saturation of the 
N-SH2 binding site. Similarly, in the presence of ITSM, CSPs of 
N-SH2 peaks occurred at higher peptide concentrations than those 
producing CSPs of the C-SH2 peaks (fig. S5, B to G).
Because of the different CSPs induced by ITIM and ITSM on 
both N-SH2 and C-SH2, the binding of the two phosphorylated 
Fig. 3. SHP2 activation in vitro by different PD-1–derived phosphopeptides. (A) DiFMUP-based activation assays of WT SHP2 with increasing concentrations of ITIM, 
ITSM, ITIM-[dPEG4]2-ITSM, and ITSM-[dPEG4]2-ITSM peptides. (B and C) DiFMUP-based activation assay of the SHP2-R32A (B) or the SHP2-R138A mutant (C) with increas-
ing concentrations of ITIM, ITSM, and ITIM-[dPEG4]2-ITSM. In (A) to (C), the individual data points represent mean values with the error bars corresponding to the SEM of 
three independent experiments, each performed in triplicate. (D) EnzChek-based phosphatase activity assay of SHP2224–541 with peptides at concentrations of 25, 100, 
200, and 400 M. The slope values from the linear range of the kinetic curves are plotted as initial velocities. The individual data points represent mean values with error 
bars corresponding to the SEMs of three independent experiments (each performed in duplicate) for all cases except for ITIM-[dPEG4]2-ITSM, where only two indepen-
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motifs of ITIM-[dPEG4]2-ITSM to each of the SH2 domains of 
SHP21–220 could be closely monitored during the titration (Fig. 4A). 
Using a protein concentration of 200 M, we found that C-SH2 
exclusively binds ITSM at all protein:peptide ratios, while a more 
complex picture emerged for N-SH2. At peptide concentrations 
<200 M, N-SH2 was either unbound or bound to ITIM; at peptide 
concentrations >200 M, the amount of ITIM-bound N-SH2 in-
creased as expected, but evidence of N-SH2 binding to ITSM also 
started to appear. Raising the peptide concentration to 400 M and 
higher resulted in an increase in the intensity of the peaks cor-
responding to N-SH2–ITSM at the expense of those corresponding 
to N-SH2–ITIM. The latter had disappeared with a fourfold excess 
of peptide, due to the complete displacement of ITIM by ITSM, 
resulting in the formation of a 1:2 protein:peptide complex.
Next, we measured diffusion-ordered spectroscopy and 2D 1H-15N 
spectra of protein:peptide mixtures at 1:1.2 molar ratio over a dilu-
tion series corresponding to protein concentrations of 100, 53, 28, 
14, and 5 M. The diffusion coefficients (D) increased steadily upon 
dilution and remained stable after the second-to-last dilution point 
(Fig. 4C). At the concentration of 14 M, the value of the diffusion 
coefficient was compatible with a 1:1 SHP21–220–ITIM-[dPEG4]2-
ITSM complex, while at higher concentration, the D values suggested 
the formation of oligomers. In the absence of ITIM-[dPEG4]2-ITSM, 
SHP21–220 remained monomeric at all concentrations, indicating 
that these oligomers are held together by the two phosphorylated 
motifs of a single molecule of ITIM-[dPEG4]2-ITSM. The forma-
tion of multimers in the presence of ITIM-[dPEG4]2-ITSM was also 
observed for SHP21–525 (fig. S6).
The dependence of the stoichiometry of the complex on protein 
concentration was confirmed by size-exclusion chromatography (SEC) 
coupled with multiangle light scattering (MALS). We measured two 
equimolar mixtures of SHP21–220 and ITSM-[dPEG4]2-ITSM, prepared 
at concentrations of 10 and 100 M. For this experiment, we used 
the bidentate ITSM-[dPEG4]2-ITSM peptide, instead of ITIM-[dPEG4]2-
ITSM, to avoid the loss of binding between the protein and ITIM 
that could occur at low concentrations on the SEC column. The 
SEC-MALS profile of the mixture prepared at 100 M displayed a 
significant degree of heterogeneity, as detected by the misalignment 
of the light scattering and refractive index curves, and a mass distri-
bution ranging from 42 to 35 kDa (Fig. 4B, left peak). The solution 
prepared at 10 M was far more homogeneous, with a molecular 
weight of 30 to 32 kDa (Fig. 4B, middle peak). These data confirm 
that the oligomerization of the protein-peptide complex is dependent 
on protein concentration with concentrations <<100 M favoring 
the formation of 1:1 particles.
Next, we tested whether the transition from oligomeric protein- 
peptide complexes to a homogeneous 1:1 complex was visible in the 
1H-15N spectra of SHP21–220 by monitoring SHP21–220 1H-15N peaks 
of a protein:peptide mixture at 1:1.2 molar ratio while decreasing 
the total concentration. Upon dilution, we observed several CSPs 
(Fig. 4D), all of which mapped to amino acids localized at the inter-
face between the two SH2 domains rather than to the N-SH2 or 
C-SH2 peptide binding sites (Fig. 4F). This demonstrates that the 
formation of the 1:1 SHP21–220–ITIM-[dPEG4]2-ITSM complex, where 
both ITIM and ITSM of the bidentate peptide are bound to the N-SH2 
and C-SH2 domains of one SHP21–220 molecule, generates a new 
interface between the SH2 domains. These concentration-dependent 
CSPs were not present when titrating a mixture of N-SH2 and 
C-SH2 with ITIM-[dPEG4]2-ITSM or C-SH2 with ITSM (Fig. 4D). 
In addition, the CSPs disappeared from the 1H-15N spectrum of 
SHP21–220 upon addition of a twofold molar excess of ITIM-[dPEG4]2-
ITSM, as expected, due to the formation of the 1:2 protein:peptide 
complex, in which both SH2 domains are bound to ITSM.
The relative orientation of the SH2 domains in the autoinhibited 
SHP21–525 structure of PDB entry 2SHP is not compatible with the 
simultaneous binding of the two phosphorylated motifs of ITIM-
[dPEG4]2-ITSM to both SH2 domains, due to the spatial constraint 
imposed by the length of the linker (Fig. 4E). In the structure of the 
constitutively active SHP2-E76K mutant solved recently (26, 27), 
the reorientation of both N-SH2 and C-SH2 domains relative to the 
PTP domain leaves the active site of the PTP domain fully accessible 
to the substrate (PDB entry 6CRF; fig. S7). However, this arrange-
ment of the N-SH2 and C-SH2 domains is also incompatible with 
the simultaneous binding of the two phosphorylated motifs of 
ITIM-[dPEG4]2-ITSM, as the distance of 65 Å between the C-terminal 
end of ITIM and the N-terminal end of ITSM would be much longer 
than the linker (~40 Å). In contrast, the structure of full-length 
SHP1 seen in PDB entry 3PS5 (28) would allow binding of both 
ITIM and ITSM of one bidentate peptide molecule to its SH2 
domains (Fig. 4E and fig. S7). In PDB entry 3PS5, the N-SH2 do-
main is moved away from the PTP domain and located behind the 
C-SH2 domain, which is rotated by 110° with respect to the struc-
ture of PDB entry 2SHP; in this conformation, the PTP catalytic 
pocket is wide open and accessible to the substrate.
Both ITIM and ITSM are necessary for full SHP2 activation
Our in vitro studies support the notion that both ITIM and ITSM 
are required for full activation of SHP2, which leads to suppression 
of T cell activation. To test this hypothesis in T cells, we used a func-
tional readout of the consequences of ITIM and ITSM mutations on 
PD-1–mediated suppression of T cell receptor (TCR) signaling 
(Fig. 5A).
The Jurkat T cell line contained some cells with endogenous 
PD-1 expression in the unstimulated state, as detected by flow cyto-
metry; and hence, cells were first fluorescence-activated cell sort-
ing (FACS)–sorted to obtain only those that were PD-1 negative. 
These cells were then lentivirally transduced with Flag-tagged 
WT PD-1, PD-1–Y223F (called PD-1 ITIMmut), or PD-1–Y248F 
(called PD-1 ITSMmut) and sorted for green fluorescent protein 
(GFP) expression (the lentiviral plasmids also encoded for GFP in 
addition to the PD-1 variants). Similar PD-1 expression levels were 
confirmed by flow cytometry, using anti–PD-1 antibody staining 
(Fig. 5B). The Jurkat TCR can be stimulated with major histocompat-
ibility complex (MHC) II molecules loaded with the superantigen 
staphylococcal enterotoxin E (SEE). We used human Raji B cells 
as MHC II– presenting cells (29); these lack endogenous PD-L1 ex-
pression and were therefore lentivirally transduced with PD-L1 and 
enriched by GFP sorting. Jurkat and Raji cells also express the CD28 
receptor and its ligand B7.1, respectively. Thus, SEE-loaded MHC II 
stimulates the TCR and B7.1 stimulates CD28, while PD-L1 binds to 
PD-1 (or the PD-1 mutants) to suppress the TCR- and CD28-derived 
activation signals (Fig. 5A). This system was used in a previous 
study of suppression of TCR/CD28 signaling by PD-1 (16).
First, we tested how the PD-1 variants influenced the binding of 
endogenous SHP2 in the Jurkat T cells. The PD-L1–expressing Raji 
B cells were loaded with SEE and incubated with the PD-1 variant–
expressing Jurkat T cells for 0, 2, or 10 min. The Flag-tagged PD-1 
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N-SH2 ITIM C-SH2 ITSM
Fig. 4. A new N-SH2:C-SH2 interface forms upon simultaneous binding of ITIM-[dPEG4]2-ITSM to both SH2 domains of SHP21–220. (A) Excerpt from the 
1H-15N NMR spectrum of SHP21–220 in the presence of different stoichiometric ratios of ITIM-[dPEG4]2-ITSM shows two sets of peaks for amino acids 1 to 110, match-
ing those of the N-SH2–ITIM and N-SH2–ITSM complexes. With excess peptide, the ITSM-bound peak becomes dominant. Colors represent protein:peptide molar 
equivalents. (B) Size-exclusion chromatography (SEC)–multiangle light scattering (MALS) profiles of equimolar SHP21–220:ITSM-[dPEG4]2-ITSM mixtures at either 
10 or 100 M, together with the profile of the unbound protein. (C) Translation diffusion coefficients measured by NMR DOSY (diffusion-ordered spectroscopy) for 
equimolar SHP21–220:ITIM-[dPEG4]2-ITSM mixtures at concentrations in the 5 to 100 M range. (D) Top left: S189 CSPs upon dilution of a 1:1.2 SHP21–220:ITIM-
[dPEG4]2-ITSM mixture. Shades of blue represent different concentrations. Top right: S189 CSPs upon titration of increasing molar ratios of ITIM-[dPEG4]2-ITSM 
([SHP21–220] = 100 M). The straight lines and arrows indicate concentration-dependent CSPs and CSPs from the unbound to the bound state, respectively. The 
peak indicative of the new interdomain interface reaches its maximum intensity at equimolar SHP21–220:ITIM-[dPEG4]2-ITSM and disappears with excess pep-
tide. Bottom left and right: Titration of a mixture of isolated N-SH2 and C-SH2 at 200 M each (left) or C-SH2 alone (right) with ITIM-[dPEG4]2-ITSM. The S189 peak 
corresponding to the new interdomain interface is not visible. (E) Homology models of SHP1–220 with ITIM and ITSM bound to the N-SH2 and C-SH2 domain, respec-
tively, obtained by superposition of the N-SH2–ITIM and C-SH2–ITSM structures on the respective SH2 domains of PDB entry 2SHP (top, autoinhibited state of 
SHP2) and PDB entry 3PS5 (bottom, open state of SHP1). The dashed lines represent the distance between the ITIM C terminus and the ITSM N terminus. The length 
of the extended connecting linker in PD-1 is ~40 Å. (F) Superposition of the SHP21–220 models of (E) aligned on the C-SH2 domain (green). The N-SH2 domains 
from PDB entries 2SHP and 3PS5 are in blue and cyan, respectively. Residues in orange show CSPs upon dilution of the equimolar SHP21–220:ITIM-[dPEG4]2-ITSM 
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Fig. 5. Effect of PD-1 mutants on SHP2 binding and TCR-induced T cell activation. (A) Experimental setup for quantifying the inhibitory effect of PD-1 on TCR-mediated 
T cell activation. Raji B cells were lentivirally transduced with PD-L1 and used as antigen-presenting cells. Jurkat T cells were transduced with either WT PD-1, PD-1 ITIMmut, 
PD-1 ITSMmut, or an empty vector. For TCR stimulation, the B cells were incubated with superantigen [staphylococcal enterotoxin E (SEE)] and cocultured with the T cells. 
Upon activation of PD-1, ITIM and ITSM become phosphorylated and recruit SHP2. (B) Quantification of the surface expression of WT PD-1 (red), PD-1 ITIMmut (orange), and 
PD-1 ITSMmut (blue) in the different Jurkat cell lines. Cells containing an empty vector are used as negative control. (C) Coimmunoprecipitation (IP) experiment demonstrating 
SHP2 binding to the PD-1 variants after incubation of T cells with SEE-loaded B cells (30 ng/ml) for the indicated time points. PD-1, Flag, and SHP2 protein levels were 
analyzed; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. (D) CD69 expression levels of the Jurkat T cell lines (WT PD-1, PD-1 ITIMmut, 
and PD-1 ITSMmut) were measured by flow cytometry after 5 hours of stimulation with B cells preincubated with different SEE concentrations. The mean fluorescence intensity 
(MFI) is shown. (E) Relative interleukin-2 (IL-2) levels in the supernatant of the Jurkat cell cultures (WT PD-1, PD-1 ITIMmut, and PD-1 ITSMmut) were measured by enzyme-linked 
immunosorbent assay (ELISA) after 24 hours of stimulation with SEE-loaded B cells. Statistics are based on two-way analysis of variance (ANOVA) and Bonferroni multiple 
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coprecipitation of SHP2 was analyzed by SDS–polyacrylamide gel 
electrophoresis (PAGE) and immunoblotting (Fig. 5C). Upon 
coculture of the two cell lines, SHP2 was recruited to WT PD-1, as 
shown before (16). Similar levels of SHP2 recruitment were observed 
with PD-1 ITIMmut, while SHP2 could not be coprecipitated with PD-1 
ITSMmut. As a control, immunoblotting with anti-PD-1 antibodies 
showed similar amounts of PD-1. This result indicates that ITSM is 
required for SHP2 recruitment by PD-1, while ITIM is dispensable.
Second, we interrogated the functional role of ITIM and ITSM 
in suppressing TCR/CD28 signaling. The PD-1 variant–expressing 
Jurkat cells were stimulated with the PD-L1–expressing Raji B cells 
using different concentrations of SEE for 5 hours. TCR-induced ex-
pression of the early activation marker CD69 was quantified by flow 
cytometry. In the absence of PD-1, stimulation with SEE resulted in 
a dose-dependent up-regulation of CD69 (Fig. 5D), while presence 
of WT PD-1 reduced the level of CD69 expression, most likely due 
to recruitment and activation of SHP2. Expression of PD-1 ITSMmut, 
which did not recruit SHP2, was unable to reduce CD69 levels com-
pared to the empty vector control. In contrast, PD-1 ITIMmut, which 
recruited SHP2, was able to reduce CD69 expression, albeit to a lesser 
extent than WT PD-1. This result indicates that ITIM, despite being 
dispensable for SHP2 binding, does play a role in PD-1 function. 
As a control, the CD69 levels of the Raji B cells were not affected by 
the coculture with the T cells (fig. S8).
Third, we quantified the TCR-induced secretion of the late activa-
tion marker interleukin-2 (IL-2) by an enzyme-linked immunosorbent 
assay (ELISA). To this end, we cocultured the Jurkat and SEE-loaded 
Raji cells for 24 hours, to allow IL-2 to accumulate in the culture 
supernatant. The results recapitulated those obtained by CD69 
quantification (Fig. 5, D and E). Briefly, WT PD-1 reduced TCR- 
induced IL-2 production, while the PD-1 ITSMmut did not reduce 
IL-2 levels. In contrast, PD-1 ITIMmut was able to inhibit TCR 
signaling but to a lesser extent than that by WT PD-1.
In summary, the functional experiments demonstrated that mu-
tation of ITSM abolishes PD-1 signaling, while mutation of ITIM 
only reduces PD-1 signaling. These results correlate well with the 
lack of SHP2 coimmunoprecipitation with PD-1 ITSMmut, while 
PD-1 ITIMmut did bind SHP2. This correlation, together with our 
structural and biochemical data, indicates that the function of ITIM 
in supporting the PD-1–mediated suppression of the immune response 
is to enable full activation of SHP2 phosphatase activity.
DISCUSSION
Targeting of PD-1 by monoclonal antibodies that disrupt interaction 
with its ligands has proven a successful therapeutic strategy for several 
cancers (30). Nevertheless, the cost of such therapies imposes a burden 
on public health care, and there remains an unmet demand for afford-
able small-molecule drugs that are able to disrupt PD-1 signaling in 
T cells. Targeting SHP2, as the immediate downstream partner of 
PD-1, holds promise for the development of a new class of immune 
modulators. While this strategy has been recently questioned by 
Rota et al. (31), who used cells with chronically knocked-down SHP2 
and found that the phosphatase is dispensable for PD-1 signaling 
in vivo, the concept is supported by many studies demonstrating 
that SHP2 plays an important role in T cell activation (14–16, 18, 19).
The design of small molecules targeting the SHP2–PD-1 interaction 
during immune response relies on the knowledge of the structure of 
the SHP2–PD-1 complex as well as on the discovery of the functional 
determinants of the signaling process. However, while the binding 
of SHP2 to PD-1 was shown to depend on its two SH2 domains 
recognizing the phosphorylated ITIM and ITSM of the cytoplasmic 
tail of PD-1, the exact roles of the C-SH2 domain of SHP2 and the 
ITIM of PD-1 could not be described unambiguously. In addition, 
the architecture of the SHP2–PD-1 complex, which contains two pY 
binding sites (the N-SH2 and C-SH2 domains of SHP-2) and two 
pY-peptide motifs (ITIM and ITSM of PD-1), remained obscure.
Here, we used a combination of structural and functional studies 
in vitro and in cells to determine the mechanism of activation of 
SHP2 by the cytoplasmic tail of PD-1. Using NMR spectroscopy 
and calorimetry, we find that ITSM has the highest affinity for both 
SH2 domains with a 10-fold preference for C-SH2. On the other 
hand, ITIM binds preferentially to N-SH2, although 10-fold weaker 
than ITSM. In agreement with these relative affinities, ITSM is a 
stronger activator of SHP2 activity in vitro and is indispensable for 
PD-1 signaling in cells. However, our structural and functional data 
demonstrate that full activation of the phosphatase is dependent on 
the simultaneous binding of both ITIM and ITSM, connected by 
a linker as parts of the same molecule, to SHP2, with each phos-
phorylated motif engaging one of the SH2 domains. ITSM binds to 
C-SH2 with strong affinity, recruiting PD-1 to SHP2, while ITIM 
binds to N-SH2, displacing it from the PTP catalytic pocket and 
activating the phosphatase (Fig. 6). In the absence of phosphorylated 
ITIM, ITSM binds to both C-SH2 and N-SH2, with a 10-fold prefer-
ence for C-SH2. The N-SH2–ITSM binding event also activates the 
phosphatase, but this second activation mechanism (Fig. 6) is less 
efficient than the one involving the bidentate peptide, both in vitro 
and in cells. On the basis of our data, we can propose two reasons 
for this. First, activation of the phosphatase can be achieved by 
binding of phosphopeptides to only the N-SH2 domain, inducing 
the conformational change of the EF loop that releases N-SH2 from 
the PTP active site (2). However, this event has not been shown to 
yield a stable open conformation but likely generates a number of 
conformations, in some of which the N-SH2 domain would still 
partially occlude access to the PTP active site (Fig. 6). In contrast, 
simultaneous binding of ITIM and ITSM to both N-SH2 and C-SH2 
yields a stable open conformation, with N-SH2 locked far away 
from the PTP active site. Second, in the absence of a second phos-
phorylated site, binding of ITSM to N-SH2 is outcompeted by the 
C-SH2 domain, which binds ITSM more strongly than does N-SH2. 
In vitro, the isolated ITIM can activate SHP2 through the same 
mechanism as ITSM. The failure to detect any SHP2-stimulating 
activity in the absence of phosphorylated ITSM in cells can be 
explained by the lower affinity of ITIM for N-SH2 as compared to 
ITSM, which is not sufficient to yield a measurable activation signal. 
Similarly, the low affinity of ITIM for both N-SH2 and C-SH2 (Kd > 
1 M) rationalizes the inability of PD-1 ITSMmut to pull down 
SHP2 in immunoprecipitation experiments.
The model of activation by the bidentate peptide shown in Fig. 6 is 
fully supported by the NMR data. Titration of the SHP21–220 construct, 
containing both SH2 domains, with the bidentate ITIM-[dPEG4]2-
ITSM peptide shows that ITSM binds preferentially to C-SH2, while 
the N-SH2 domain is recruited by ITIM. The spectra show no indica-
tion of ITIM binding to the C-SH2 domain at any stoichiometric 
ratio or concentration, confirming the arrangement of the two 
binding motifs of the bidentate peptide as shown in Fig. 6. Overall, 
our data provide structural and biochemical support for the two-
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is first recruited to PD-1 through the C-SH2–ITSM interaction and 
then activated by the N-SH2–ITIM interaction. However, there 
is no evidence of the temporal order of the two binding events, 
which could also occur concomitantly or involve additional inter-
mediate steps.
Our biophysical data demonstrate that the SHP21–220–ITIM-
[dPEG4]2-ITSM complex, with ITIM and ITSM recognized by 
N-SH2 and C-SH2, respectively, occurs only at concentrations below 
15 M. At higher concentrations, SHP21–220 forms multimers, held 
together by ITIM-[dPEG4]2-ITSM bridging two SHP21–220 molecules 
(Fig. 4, B and C). This fact implies that the formation of the stable 
1:1 SHP21–220–ITIM-[dPEG4]2-ITSM complex, following the initial 
encounter of the protein with the peptide, occurs at a slower rate 
than an encounter with a second protein molecule at 15 M con-
centration (diffusion-limited kon × protein concentration = 5 × 
108 M−1 s−1 × 15 × 10−6 M = 7500 s−1). The relatively slow rate of the 1:1 
complex formation suggests the involvement of significant conforma-
tional rearrangements in the protein. Accordingly, the NMR data 
reveal the formation of a new interaction surface between the N-SH2 
and C-SH2 domains in the SHP21–220–ITIM-[dPEG4]2-ITSM complex. 
The change in the orientation of the SH2 domain is required because 
of the restrictions imposed by the length of the linker connecting 
ITIM and ITSM.
All the above data suggest that full activation of SHP2 by simul-
taneous binding of both ITIM and ITSM is regulated at several levels. 
First, the N-SH2 binding affinity of ITIM is less than that of ITSM, 
as a bidentate peptide containing two ITSMs (ITSM-[dPEG4]2-ITSM) 
activates SHP2 more efficiently than ITIM-[dPEG4]2-ITSM. The fact 
that such a combination of strong binding motifs does not exist in 
nature points to the necessity of tuning SHP2 activation to avoid 
hyperactivity. Accordingly, the SH2 domains are generally sub-
optimal with respect to phosphopeptide affinity, while they may 
be optimized for regulation (32). Second, SHP2 dephosphorylates 
ITIM more efficiently than ITSM, providing an additional way 
to tune down SHP2 activation, when required. Third, the full acti-
vation of SHP2 requires a slow conformational change, which 
is outcompeted by binding of ITIM to a second protein molecule at 
concentrations of SHP2 higher than 15 M. While we cannot prove 
whether this mechanism is relevant in cells, it has been reported 
that the concentration of SHP2 in mammalian cells is in the micro-
molar range (33), where the regulation mechanism based on the 
oligomerization of the SHP-2–PD-1 complex would be applicable. 
Thus, it is conceivable that the formation of inactive or moderately 
active oligomers could contribute to the down-regulation of SHP2 
activation in the presence of high amounts of either the phosphatase 
or PD-1. In support of this, Peled et al. (17) failed to find a correlation 
between PD-1 expression levels and TCR signaling in different 
T cell pools.
Previous reports have failed to reach consensus on the relevance 
of ITIM for SHP2 activation (15–19). Our results indicate that these 
discrepancies may be attributable to a fine regulation of the ITIM- 
dependent activation process, which is differently affected by the 
exact experimental setups. In addition, in the absence of phospho-
rylated ITIM, a second activation mechanism becomes relevant 
(Fig. 6), which, while less efficient, can have a compensatory effect 
within given cellular parameters, such as protein concentration or 
phosphorylation levels.
SHP2 is activated also by other bidentate phosphopeptides, such 
as that present in insulin receptor substrate-1 (IRS-1) in insulin sig-
naling (34). It is conceivable that the mechanism of regulation of 
SHP2 activity described here applies generally to SHP2 activation 
by bidentate phosphopeptides in multiple contexts, albeit with 
different structural and biophysical parameters. In the case of the 
SHP2–PD-1 interaction, we believe that the interface between the 
N-SH2 and C-SH2 domains, which is formed upon full activation 
and holds SHP2 in the open active conformation, represents a po-
tential target to affect SHP2 activation selectively in the context of 
PD-1 signaling (35). Preventing the formation of this interface 
would decrease, but not abolish, PD-1 signaling. This strategy could 
be exploited as part of a combination therapy to reduce cancer im-
mune evasion, while sensitizing cancer cells to other drugs and pre-
venting the side effects caused by full SHP2 inhibition.















































Fig. 6. Two activation mechanisms of SHP2 by PD-1. Binding of phosphoproteins 
activates the autoinhibited form of SHP2 (left) by acting to remove the N-SH2 
domain from the PTP binding site. Activation can occur in two ways. Top right: 
When the doubly phosphorylated PD-1 tail binds simultaneously to both SH2 
domains of SHP2, the phosphatase adopts a stable open conformation, where the 
N-SH2 is locked behind the C-SH2 due to the restraint imposed by the linker 
connecting ITIM and ITSM. Bottom left: When ITIM is dephosphorylated or ITSM is 
present in large excess, ITSM binds to the N-SH2 domain, thereby weakening its 
interaction with the PTP domain. However, in the absence of the divalent binding 
event, the N-SH2 domain is not locked behind the C-SH2 domain and may adopt 
many orientations (depicted schematically by three representative orientations 
connected by the gray double-headed arrows). In some of these orientations, the 
N-SH2 domain may occupy the space close to the PTP domain, partially occluding 
access to its active site. The switch between the two mechanisms may represent a 
way to regulate the efficiency of SHP2 activation depending on the concentration 
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To elucidate the mechanism of SHP2 activation by PD1 and verify 
it in cells, we structured the work in three packages: structural, bio-
chemical, and cellular experiments. The experimental design for 
each package is explained in the respective sections.
Structural studies
Experimental design
The protein-peptide complex structures were solved either by NMR 
or x-ray crystallography. The interaction of the N-SH2 and C-SH2 
domains as well as of SHP21–220 with ITIM, ITSM, and ITIM-[dPEG4]2-
ITSM was analyzed by NMR. The multimerization state of the 
complexes was studied by SEC-MALS. The binding affinities were 
determined by NMR and calorimetry.
Protein expression and purification
For full-length SHP2, the DNA sequence of SHP2, isoform 2 (protein 
sequence in UniProtKB accession code Q06124-2), was amplified and 
cloned into the pETM11-Sumo3 expression vector (European Molec-
ular Biology Laboratory collection) using Bam HI and Xho I restric-
tion sites. The DNA for the SHP21–525 mutant, with the deletion of 
the C-terminal tail,  was generated using forward primer 
5′-TCTTCTTCAATACGACGCTACAGGGTTTCGATATAAT-
GC-3′ and reverse primer 5′-GCATTATATCGAAACCCTGTAG-
CGTCGTATTGAAGAAGA-3′. The SHP21–525 R32A and R138A 
mutants were generated with the Quik Change Lightning Site-Directed 
Mutagenesis protocol (Agilent Technologies). All constructs were 
confirmed by DNA sequencing.
Plasmid DNA encoding SHP21–525 was transformed into BL21 
DE3 Escherichia coli, from which a single colony was selected to 
inoculate a 50-ml starter culture of LB with kanamycin (50 g/ml), 
and allowed to grow overnight. The following morning, 10 ml of the 
saturated culture was used to inoculate 1 liter of LB with kanamycin 
(50 g/ml). At an OD600 (optical density at 600 nm) of 0.5 to 0.6, 
expression of SHP21–525 was induced by the addition of 0.1 mM 
isopropyl--d-1-thiogalactopyranoside (IPTG). Expression was con-
tinued overnight at 20°C. The cells were then pelleted at 4°C and 
4000 rpm for 40 min; resuspended and incubated for 15 min in 
30 ml of ice-cold 50 mM tris-HCl (pH 7.6), 1 M NaCl, 10% glycerol, 
5 mM -mercaptoethanol, 10 mM imidazole, and an EDTA-free 
protease inhibitor cocktail tablet (Roche); and then lysed via sonication. 
Total cell lysate was clarified at 18,000 rpm for 40 min at 4°C; the 
supernatant was filtered, then loaded onto a HisTrap FF (GE 
Healthcare) column washed with buffer A [50 mM tris-HCl (pH 7.6), 
1 M NaCl, 2% glycerol, 5 mM -mercaptoethanol, and 10 mM 
imidazole], and eluted with a gradient of buffer B [50 mM tris-HCl 
(pH 7.6), 1 M NaCl, 2% glycerol, 5 mM -mercaptoethanol, and 
500 mM imidazole]. The N-terminal histidine tag was then cleaved 
using sentrin-specific protease 2 protease (1:1000 protease/protein 
ratio) overnight in buffer C [20 mM tris-HCl (pH 8.0), 50 mM 
NaCl, and 5 mM -mercaptoethanol]. The next day, the cleaved 
protein was loaded onto an ion-exchange column (HiTrap Q FF), 
washed with buffer C, and eluted with a gradient of 50 to 500 mM 
NaCl. Pure fractions were pooled, concentrated to 0.5 ml, and 
purified further on a HiLoad Superdex 200 16/600 size-exclusion 
column (GE Healthcare) equilibrated into 50 mM Hepes (pH 7.6), 
150 mM NaCl, and 1 mM EDTA. Fractions were collected in 1.5-ml 
increments and assessed for purity via PAGE, and pure fractions 
were concentrated, dispensed into 10- to 50-l single-use aliquots, 
and stored at −80°C with 20% glycerol and 1 mM dithiothreitol 
(DTT).
Human SHP2 domains N-SH2 (1 to 105, 11.9 kDa), C-SH2 
(106 to 220, 13.3 kDa), and SHP21–220 were subcloned into the 
pETM22 plasmid, which bears a cleavable His6-tagged thioredoxin 
tag for improved solubility and folding. Expression was performed 
in BL21(DE3) E. coli strains, induced with 0.2 mM IPTG at 20°C 
for 18 hours. The cells were induced at an OD600 of 0.6 to 0.8. Prepara-
tion of uniformly 15N,13C-labeled protein for NMR studies was 
achieved by growing the bacteria in M9 minimal medium contain-
ing kanamycin (50 g/ml), 15NH4Cl (1 g/liter), and 13C-d-glucose 
(4 g/liter). Isotopes were purchased from Cambridge Isotope Lab-
oratories. After harvesting, cell pellets were stored at −20°C until 
purification.
Production of deuterated SHP21–220 was achieved with the same 
protocol, using BL21(DE3) Tuner E. coli strains. Sparse deuteration 
was accomplished by supplying the bacteria with a protonated carbon 
source and by growing them in 70% D2O (for a final deuteration 
level of 50%) or in 99% D2O (for a final deuteration level of >80%). 
D2O was purchased from Eurisotop. Perdeuterated isoleucine, leucine, 
and valine (ILV)–labeled SHP21–220 was produced growing the bacteria 
in fully deuterated M9 minimal medium and supplying them with 
d7-d-glucose (Cambridge Isotope Laboratories). At an OD600 of 
0.5, methyl group precursors—-ketobutyric acid, sodium salt 
(60 mg/liter) and -ketoisovaleric acid, sodium salt (120 mg/liter)—
were added, and expression was then induced at an OD600 of 0.6 
(20°C for 18 hours). For side-chain assignment experiments, the 
following labeling scheme was adopted: -ketobutyric acid, sodium 
salt (13C4, 98%; 3,3-D2, 98%) and -ketoisovaleric acid, sodium salt 
(1,2,3,4-13C4, 99%; 3,4′,4′,4′-D4, 97 to 98%), whereas terminally labeled 
precursors were used for nuclear Overhauser effect spectroscopy 
(NOESY) experiments: -ketobutyric acid, sodium salt (methyl-13C, 
99%; 3,3-D2, 98%) and -ketoisovaleric acid, sodium salt (3-methyl-13C, 
99%; 3,4,4,4-D4, 98%). Cell pellets were resuspended in wash buffer 
[1 M NaCl, 50 mM tris, 2% glycerol, 10 mM imidazole, and 5 mM 
-mercaptoethanol (pH 7.6)] with one tablet of EDTA-free protease 
inhibitor cocktail (Roche), 100 g of lysozyme (Roth), and 50 g of 
deoxyribonuclease (DNAse) [New England Biolabs (NEB)]. Lysis was 
performed on a high-pressure homogenizer (Avestin Emulsiflex C3). 
The lysate was spun at 19,000 rpm for 1 hour, and the filtered super-
natant was loaded on a HisTrap HP column (GE Healthcare), 
equilibrated with wash buffer. Elution of the His6-tagged protein 
constructs was achieved with an imidazole gradient of 10 to 300 mM 
over a volume of 60 ml. Fractions containing the protein of interest 
were pooled, concentrated to approximately 15 ml, and loaded on a 
HiPrep 26/10 desalting column (GE Healthcare) to remove the 
excess of imidazole. The thioredoxin tag was cleaved by incubation 
with 3C protease (1:100 protease/protein ratio) at 4°C overnight. 
Purification continued with a second Ni2+-affinity chromatography 
step followed by SEC on a HiLoad 16/600 Superdex 75 pg (GE 
Healthcare) column, equilibrated with NMR buffer [150 mM NaCl 
and 100 mM MES (pH 6.8)]. Subsequently, the protein was concen-
trated to the desired concentration and either used directly for 
NMR experiments or flash-frozen with liquid nitrogen for long-
term storage at −80°C.
The PTP domain of SHP2 (225 to 525) was expressed in BL21(DE3) 
Tuner E. coli cells and used in the activity assays. Bacteria were 
grown at 37°C until they reached an OD600 of 0.6 to 0.8. Protein 









Marasco et al., Sci. Adv. 2020; 6 : eaay4458     31 January 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
11 of 15
16°C for 18 to 20 hours. After harvesting, cell pellets were resuspended 
in ice-cold wash buffer [50 mM tris-HCl, 1 M NaCl, 5% glycerol, 10 mM 
imidazole, and 5 mM -mercaptoethanol (pH 7.6)], with one tablet 
of EDTA-free protease inhibitor cocktail (Roche), 100 g of lysozime 
(Roth), and 50 g of DNAse (NEB). Lysis was performed with a 
high-pressure homogenizer (Avestin Emulsiflex C3). The lysate was 
spun at 19,000 rpm for 1 hour, and the filtered supernatant was 
loaded on a HisTrap HP column (GE Healthcare), equilibrated with 
wash buffer. Elution was achieved with a step gradient of 100% 
elution buffer [50 mM tris-HCl, 1 M NaCl, 5% glycerol, 500 mM 
imidazole, and 5 mM -mercaptoethanol (pH 7.6)]. Cleavage of the 
thioredoxin tag was performed overnight at 4°C with 3C protease, 
while the protein sample was being dialyzed against 2 liters of wash 
buffer. Purification continued with a second Ni2+-affinity chroma-
tography step followed by SEC on a HiLoad 16/600 Superdex 200 pg 
column (GE Healthcare), equilibrated with 50 mM Hepes (pH 7.6), 
150 mM NaCl, and 1 mM EDTA. Subsequently, the protein was 
concentrated to the desired concentration and either used directly 
for the activity assays or flash-frozen with liquid nitrogen for long-
term storage at −80°C.
Peptides
The EGFR peptide (Ac-DADEpYLIPQQG-NH2) was synthesized 
in-house using standard Fmoc solid-phase peptide synthesis in a 
MultiPep RSi peptide synthesizer from Intavis Bioanalytical Instruments 
and purified by high-performance liquid chromatography (HPLC; 
Agilent Technologies, 1260 Infinity series). The other peptides were 
purchased from Caslo ApS (Lyngby, Denmark). The sequences of 
the peptides were as follows: ITIM, Ac-FSVD(pY)GELDFQ-NH2, 
ITSM, Ac-EQTE(pY)ATIVFP-NH2, diphosphorylated peptide ITIM-
[dPEG4]2-ITSM, Ac-FSVD(pY)GELDFQ-(dPEG4)-(dPEG4)- 
EQTE(pY)ATIVFP-NH2, diphosphorylated peptide ITSM- 
[dPEG4]2-ITSM, Ac-EQTE(pY)ATIVFP-(dPEG4)-(dPEG4)- EQTE(pY)
ATIVFP-NH2. The purity obtained in the synthesis was 95 to 98% 
and was determined by HPLC using a C18 column followed by 
mass spectrometry.
NMR spectroscopy
NMR spectra were recorded at a temperature of 298 K on Bruker 
Avance III HD 600- and 850-MHz spectrometers running TopSpin 
3.2 software and equipped with N2-cooled and He-cooled inverse 
HCN triple-resonance cryogenic probe heads, respectively. NMR 
samples were prepared using protein concentrations of 0.3 to 0.8 mM 
in 150 mM NaCl and 100 mM MES (pH 6.8). Protein:peptide mixtures 
for protein-detected (isotope-edited) spectra contained peptide in a 
slight molar excess. Protein:peptide mixtures for peptide-detected 
(isotope-filtered) spectra contained protein and peptide at equimolar 
concentrations. All peptides were unlabeled. 2D 1H-15N correlation 
spectra for peptide titrations with the isolated C-SH2 and N-SH2 
domains were recorded as 15N heteronuclear single-quantum coher-
ence (HSQC) spectra (36) using uniformly 15N-labeled (U-15N) 
protein. 2D 1H-15N correlation spectra for titration of SHP21–220 
with the ITIM-[dPEG4]2-ITSM peptide were recorded as 15N-TROSY 
(transverse relaxation-optimized spectroscopy)–HSQC spectra (37) 
using U-15N,50% 2H-labeled protein. Water suppression for amide- 
detected experiments was typically achieved using the WATERGATE 
sequence in combination with water flip-back to preserve the water 
magnetization. 2D 1H-13C correlation maps for selectively methyl- 
protonated (U-2H,ILV-{Me-1H,13C}–labeled) samples were recorded 
as methyl TROSY (13C heteronuclear multiple- quantum coherence) 
spectra (38).
Protein backbone and side-chain resonances of the isolated domains 
in the unbound and peptide-bound states, as well as the unbound 
SHP21–220, were assigned from standard triple-resonance backbone 
spectra (39) [2D 15N-HSQC, 3D HNCO, 3D HNCACB, and 3D 
HN(CO)CACB] and side-chain assignment spectra [3D HC(C)H–total 
correlation spectroscopy (TOCSY), 3D H(CCCO)NH-TOCSY, and 2D 
constant-time 13C-HSQC], respectively, recorded on samples contain-
ing U-{15N,13C}–labeled protein. In addition, 2D HBCB(CGCD)HD 
and HBCB(CGCDCE)HE spectra (40) were recorded for the C-SH2–
ITSM complex to assist assignment of protein aromatic side-chain 
resonances. The 3D backbone assignment spectra for SHP21–220 
were recorded with nonuniform sampling, using Poisson-gap sam-
pling schedules generated with the web-based nus@HMS schedule 
generator from the group of Gerhard Wagner (Harvard Medical 
School).
Protein backbone resonances of SHP21–220 in complex with the 
ITIM-[dPEG4]2-ITSM peptide were assigned from TROSY-based 
triple-resonance backbone spectra [2D 15N-TROSY-HSQC, 3D 
TROSY-HNCO, 3D TROSY-HNCACB, and 3D TROSY-HN(CO)
CACB] (41) recorded with U-{15N,13C},80% 2H-labeled protein. 
ILV methyl resonances of the SHP21–220–ITIM-[dPEG4]2-ITSM 
complex were assigned with the assistance of a 3D HMCM(CG)
CBCA spectrum (39), recorded with U-{13C,15N,2H},ILV-{Me-1H} 
protein. Proton peptide resonances of the C-SH2–ITSM and SHP21–220–
ITIM-[dPEG4]2-ITSM complexes were assigned from 2D 13C,15N- 
filtered TOCSY spectra (42) recorded on samples containing 
U-{15N,13C}–labeled C-SH2 and U-{12C,14N,2H},ILV-{Me-1H,13C}–
labeled SHP21–220 proteins, respectively.
Distance restraints for structure calculation of the C-SH2–ITSM 
complex were derived from 3D NOESY–13C-HSQC, 3D 13C,15N- 
filtered NOESY–13C-edited HSQC, and 2D 13C,15N-filtered NOESY 
spectra (yielding protein intramolecular and protein-peptide inter-
molecular NOEs, protein-peptide intermolecular NOEs, and peptide 
intramolecular NOEs, respectively), recorded on C-SH2–ITSM 
samples containing U-{15N,13C}–labeled C-SH2 protein.
NMR data analysis
Uniformly sampled NMR spectra were processed with TopSpin 3.2 
(Bruker) and nmrPipe (43). Nonuniformly sampled time-domain 
data were first reconstructed using iterative soft thresholding as 
implemented in the hmsIST program (44) with the assistance of the 
Linux command line tool “parallel.” Peak-picking, resonance 
assignment, and NOESY peak assignment were done using CcpNmr 
Analysis (45).
Structure calculation and analysis
Structure calculations were performed using ARIA v2.3/CNS v1.21 
via the standard ARIA iterative assignment protocol (46). Distance 
restraints were generated from NOESY peak intensities with applica-
tion of spin diffusion correction for the calibration factors. Dihedral 
angle restraints for backbone  and  angles were generated from 
backbone chemical shifts using TALOS-N. Restraints were applied 
for residues where the TALOS-N classifications were “strong” or 
“generous,” using respective error ranges of twice and three times 
the uncertainty reported by TALOS-N. The numbers of steps for 
the hot, cool1, and cool2 stages of the molecular dynamics simulated 
annealing protocol were 20,000, 20,000, and 16,000, respectively. 
All distance restraints were used in every iteration. One hundred 
fifty structures were calculated in the final iteration, of which the 
10 lowest-energy structures were refined in explicit water to generate 
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X-ray data collection, structure determination, and refinement
X-ray diffraction experiments were carried out on the beamline 
X06DA, operated by the Paul Scherrer Institute at the Swiss Light 
Source (Villigen, Switzerland), and the diffraction images were 
recorded with a Pilatus 2M-F pixel detector (DECTRIS Ltd., 
Switzerland). Before data collection, the crystals were flash-cooled 
to 100 K and kept at this temperature during x-ray exposure. The 
x-ray wavelength used was 100 pm. To process data, the recorded 
Bragg reflections were indexed and integrated with the x-ray detection 
software (XDS) (47) followed by scaling and merging in Aimless and 
Ctruncate, both part of the CCP4 software suite (48). In both datasets, 
data processing revealed the presence of four- and twofold rotational 
symmetry elements that were arranged in a way compatible with a 
tetragonal space group of the form P4x2y2 (x: ∅, 1, 2, 3; y: ∅, 1). An 
analysis of the data with phenix.xtriage (49) revealed an issue with 
unusual intensity statistics for both datasets, which could not be ex-
plained by twinning as there are no twin operators in P4x2y2. After 
reprocessing in lower-symmetry space groups, the unusual intensity 
statistics remained in place and still could not be attributed to twin-
ning according to phenix.xtriage. They were most likely caused by 
a poor spot separation, which resulted from a combination of the 
large lattice parameter for axis c and the width of the Bragg peaks 
and which could not be overcome by adjustments to the experimental 
setup. The phase problem could be solved by molecular replace-
ment with Phaser (50) in space group P43212. However, subsequent 
refinement of the structure in P43212 resulted in too high values 
for the residuals Rwork and Rfree (both >0.35), indicating the wrong 
choice of space group. To restore the correct space group, data 
were reprocessed with intentional low symmetry and analyzed with 
Zanuda (48). However, Zanuda analysis was inconclusive, probably 
due to the fact that the parameters it used for refinement with 
Refmac5 (51) did not fit the quality of the datasets. As a consequence, 
data were reprocessed in all subgroups of space group P43212 
and subjected to refinement with Refmac5 through the PDB_REDO 
web server. This allowed us to obtain the most suitable refinement 
parameters, because PDB_REDO optimizes refinement settings such 
as geometric and B-factor restraint weights, the B-factor model, 
translation-libration-screw groups, and noncrystallographic sym-
metry restraints. The best, though still unusually high, values for 
the residuals were achieved in space group P43 with two copies of 
the N-SH2–peptide complexes in the asymmetric unit. The twofold 
symmetry axis that relates the two copies to each other was arranged 
perpendicular to the fourfold crystallographic screw axis and thus 
gave rise to the ambiguity of the space group. Throughout all the 
data processing and reprocessing, the upper resolution limits were 
assessed through careful observation of mean I/I and correlation 
coefficient (CC) ½ values. The structures were finalized in repeated 
cycles of manual building in Coot (52) and refinement in Refmac5 
using the optimized settings found with PDB_REDO. Refinement 
was stopped when Rwork and Rfree converged. The final models showed 
reasonable Ramachandran statistics with percent favored/allowed/
disallowed of 94/6/0 for N-SH2–ITSM and of 97/3/0 for N-SH2–ITIM. 
The structures of N-SH2–ITSM and N-SH2–ITIM were deposited 
with the PDB (www.rcsb.org) with accession numbers 6ROZ and 
6ROY, respectively. The complete data processing and refinement 
statistics are shown in table S1.
SEC-MALS experiments
The measurements were performed using a Superdex 200 10/300 
(GE Healthcare) column in line with Optilab T-rEX and mini-
DAWN TREOS (Wyatt). All samples were prepared in 100 mM 
MES, 150 mM NaCl, and 5 mM DTT (pH 6.8).
Isothermal titration calorimetry
ITC measurements were performed on a Nano ITC (TA Instru-
ments) in 100 mM MES and 150 mM NaCl (pH 6.8) at 25°C using 
an equilibration time of 3000 s and a stir rate of 200 rpm. The 
concentration of the SH2 domains in the cell was 0.1 mM, and the 
concentration of the peptides in the syringe was 1 mM. Analysis of 
the data was carried out with NanoAnalyze (v3.6.0, TA Instruments). 
The Kd was calculated from a single replicate, using a 1:1 binding 
model, based on the results of the NMR titrations.
Biochemical studies
Experimental design
To characterize the enzymatic activity of SHP2 in vitro in the presence 
of PD-1 ITIM and ITSM, we followed two lines of experiments. 
First, we measured the activation of SHP2 (WT and mutant forms) by 
ITIM and ITSM either in isolation (singly phosphorylated peptides) 
or combined in one molecule (doubly phosphorylated peptides). 
Different concentrations of peptides were incubated with a given 
concentration of SHP2; the enzymatic activity of SHP2 was measured 
using DiFMUP as a substrate. Second, we measured the ability of 
the catalytic domain of SHP2 (SHP2225–525 lacking the SH2 domains) 
to dephosphorylate the PD-1–derived peptides. In addition, in 
these assays, a given concentration of protein was incubated with 
different concentrations of peptides. To measure dephosphorylation, 
we used a commercial coupled enzymatic assay, in which the phosphate 
released from the peptide is used as a cofactor by a second enzyme present 
in the reaction mixture. All enzymatic measurements were carried out 
in three technical replicates and three independent experiments.
SHP2 phosphatase activity tests in the presence of peptide activators
SHP2 was diluted to 0.5 nM and treated with varying concentrations 
of either monophosphorylated ITIM peptide (10 nM to 150 M), ITSM 
(10 nM to 150 M), diphosphorylated peptide ITIM-[dPEG4]2-ITSM 
(240 pM to 200 M), or ITSM-[dPEG4]2-ITSM (25 pM to 200 M), 
in the following buffer conditions: 50 mM Hepes (pH 7.6), 150 mM 
NaCl, 1 mM EDTA, 5 mM DTT, and 0.05% Tween. The protein was 
incubated with the peptide at 25°C for 20 min, and then phosphatase 
activity was measured monitoring the dephosphorylation of DiFMUP 
(200 M, excitation at 358 nm and emission at 452 nm) on a Tecan 
Infinite M1000 PRO plate reader. For each peptide concentration, a 
control reaction without enzyme was measured and subtracted as 
blank. The initial velocity data were fit to a sigmoidal dose-response 
curve (variable slope) by means of the GraphPad software
  V =  V basal +  
  V max −  V basal   ───────────────  
1 +  10 Log( EC 50 −[Pep]×HillSlope) 
(1)
where V represents initial enzyme velocity, Vbasal is the basal 
velocity, Vmax is the maximal velocity, [Pep] is the concentration of 
the peptide activator, EC50 is the peptide concentration that yields a 
response equal to 50% of the difference between Vbasal and Vmax, 
and the HillSlope describes the steepness of the curve.
EnzCheck assay
The commercially available EnzCheck phosphate assay kit (Thermo 
Fisher Scientific) was used to measure the release of phosphate from 
the peptides under investigation. The kit was used according to the 
manufacturer’s instructions. The PTP domain of SHP2 (SHP2224–541) 
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with different concentrations of phosphopeptides for 30 min. The 
assay was conducted at 25°C in a BioTek Synergy H1 plate reader. 
The release of phosphate from the phosphopeptides was monitored 
measuring absorbance at 360 nm over time.
Cellular experiments
Experimental design
The aim of the cellular studies was to investigate whether both ITIM 
and ITSM are required for full activation of SHP2. Suppression of 
T cell activation was analyzed in lentivirally transduced stable PD-1 
WT, PD-1 ITIMmut, and PD-1 ITSMmut T cell lines after stimulation 
with superantigen-loaded Raji cells. Expression of the T cell activa-
tion marker CD69 was analyzed via flow cytometry, IL-2 secretion 
was measured via ELISA, and SHP2 recruitment to PD-1 was 
analyzed using immunoprecipitation and Western blot assays.
Lentiviral expression constructs
Human WT PD-1 (protein sequence in UniProt Q15116) and PD-1 
mutants with Y233F substitution in the ITIM (ITIMmut) and Y248F 
substitution in the ITSM (ITSMmut) were fused at the C terminus 
with the Flag tag peptide sequence DYKDDDDK. DNA sequences 
of the Flag-tagged PD-1 mutants and WT human PD-L1 (protein 
sequence in UniProt Q9NZQ7) were codon-optimized for expression 
in humans, assembled as gBlocks (Integrated DNA Technologies), 
and cloned into the pCDH-EF1-MCS-T2A-copGFP expression plasmid 
(System Biosciences) using the Xba I and Eco RI restriction sites. 
PD-1 and PD-L1 expression was coupled with a GFP reporter gene 
(copGFP) via a 2A-like sequence (T2A).
Lentiviral vector production
Human embryonic kidney–293T cells were transfected with the 
respective constructs cloned into pCDH-EF1-MCS-T2A-copGFP 
(System Biosciences) and the packaging plasmids pMD2.G and 
pCMVR8.74 (Addgene) using the transfection reagent polyethylenimine. 
The virus- containing supernatant was used for transduction of the 
immune cell lines.
Cell lines
To generate Jurkat cell lines expressing the Flag-tagged PD-1 
mutants, we sorted Jurkat cells to enrich for cells, which were both 
negative for PD-1 and positive for CD3 by costaining with anti–
PD-1 and anti-CD3 antibodies. PD-1−/CD3+ cells were transduced 
with lentivirus encoding the Flag-tagged PD-1 mutants. To obtain 
similar PD-1 expression levels, we sorted the transduced cells to 
enrich for cells with similar GFP expression. To generate Raji cells 
expressing PD-L1, cells were transduced with lentivirus encoding 
WT human PD-L1 followed by selection of the highest GFP- 
expressing cells. Jurkat cells were purchased from the American 
Type Culture Collection, and Raji cell lines were purchased from 
the German Collection of Microorganisms and Cell Cultures GmbH 
(DSMZ, Braunschweig, Germany) and maintained in culture as 
recommended by the manufacturer.
PD-1, PD-L1, and CD3 surface expression
PD-1 and PD-L1 expression was detected with biotin-coupled anti–
PD-1 (clone EH12.2H7, BioLegend) and anti-PD-L1 (clone 29E.2A3, 
BioLegend) antibody staining followed by streptavidin-allophycocyanin 
(APC) (BioLegend) staining. CD3 surface expression was detected 
by APC-conjugated anti-CD3 antibody (clone OKT3, BioLegend). 
Cells were analyzed by flow cytometry using a Gallios flow cytometer 
(Beckman Coulter). Cell sorting was performed using a BD FACS 
Aria III cell sorter (Becton Dickinson). Data were analyzed using 
the software FlowJo v10 (TreeStar Inc.).
Recruitment of SHP2 in an intact-cell costimulation experiment
PD-L1–expressing Raji cells were preincubated with superantigen 
SEE (30 ng/ml) (Toxin Technology) for 30 min at 37°C in serum-free 
media in culture dishes coated with bovine serum albumin (BSA). 
Jurkat cells were preincubated in serum-free media for 3 hours at 
37°C in BSA-coated culture dishes. Jurkat and Raji cells were re-
suspended in complete growth media supplemented with 1% fetal 
bovine serum, transferred to 1.5-ml microfuge tubes in a 1:1 ratio, 
mixed, and immediately centrifuged for 10 s at room temperature 
to initiate cell-cell contact followed by incubation at 37°C. At the 
indicated time points, the cell pellets were snap-frozen in liquid 
nitrogen after the supernatant was aspirated. The frozen cell pellets 
were stored at −20°C. To obtain unstimulated samples for the 
immunopurification experiments, Jurkat and Raji cells were treated 
in the same way as the stimulated samples but were not mixed in 
media and combined later during cell lysis. The frozen cell mixtures 
consisting of 2 × 107 Jurkat and 2 × 107 Raji cells were lysed in 500 l 
of lysis buffer containing 20 mM tris-HCl (pH 8.0), 137 mM NaCl, 
2 mM EDTA, 10% glycerol, 1× protease inhibitor cocktail, 1 mM 
phenylmethylsulfonyl fluoride, 5 mM iodoacetamide, 0.5 mM sodium 
orthovanadate, 1 mM NaF, and 0.5% Brij 96 for 30 min at 4°C, 
followed by 15-min centrifugation to pellet the nuclei and insoluble 
material. For immunoprecipitation of the Flag-tagged PD-1 
mutants, 450 l of cleared cell lysate was incubated with 5 l of protein 
G Sepharose slurry in phosphate-buffered saline (PBS) and 1 g of 
anti-Flag tag antibody overnight at 4°C. After four washes, the 
immunoprecipitated material and aliquots of the cell lysate were 
separated by 10% SDS-PAGE. The separated proteins were transferred 
to polyvinylidene difluoride membranes by semidry transfer. After 
blocking with 5% milk in PBS containing 0.1% Tween 20, the mem-
branes were incubated with antibodies against SHP2 (1:1000), PD-1 
(1 g/ml), Flag-tag (5 g/ml), and glyceraldehyde-3-phosphate de-
hydrogenase (1:2500), followed by incubation with horseradish 
peroxidase (HRP)–conjugated secondary antibodies (1:2500). Western 
blot signals were recorded using an ImageQuant LAS 4000 Mini 
(GE Healthcare).
The following antibodies and reagents were used for biochemical 
analysis: mouse anti-Flag tag (clone M2, Sigma-Aldrich), rabbit 
anti–SHP-2 (#3752, Cell Signaling Technology), rabbit anti–PD-1 
(#PA5-20350, Thermo Fisher Scientific) and HRP-coupled goat 
anti-mouse immunoglobulin G (IgG) (#A0168, Sigma-Aldrich), 
HRP-coupled donkey anti-rabbit IgG (#NA934, GE Healthcare), 
protein G Sepharose 4 fast flow (GE Healthcare), and the protease 
inhibitor cocktail from Sigma-Aldrich.
Expression of CD69
Raji cells (1 × 105) transduced with human PD-L1 were seeded per 
well in a V-shaped 96-well plate and preincubated in 1% fetal 
bovine serum starvation media with different amounts of super-
antigen SEE (30, 3, 0.3, 0.03, and 0 ng/ml). Jurkat cells transduced 
with the PD-1 mutants were stained with the cell dye eFluor670 
(eBioscience) to allow for discrimination of B and T cells in flow 
cytometry analysis. Stained Jurkat cells (1 × 105) were mixed with 
SEE-loaded B cells and centrifuged to enable cell-cell contact fol-
lowed by incubation at 37°C. After 5 hours, the cells were stained 
with pacific blue–conjugated anti-human CD69 (clone FN5O, Bio-
Legend) and phycoerythrin-conjugated anti-human CD19 (clone 
HIB19, BioLegend) antibodies and analyzed by flow cytometry to 
test for up-regulation of CD69 expression in the B and T cells. Data 
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Secretion of IL-2
Raji cells (1 × 105) transduced with human PD-L1 were preincubated 
in complete growth media supplemented with 1% fetal calf serum 
and different amounts of superantigen SEE (30, 3, 0.3, 0.03, and 
0 ng/ml) for 24 hours in V-shaped 96-wells. Relative IL-2 protein levels 
were analyzed by ELISA using the Human IL-2 Ready-SET-Go Kit 
(#88-7025-88, eBioscience) as described by the manufacturer. The 
absorbance at 450 nm was measured with a plate reader (Synergy 
BioTek). As reference wavelength, the absorbance at 570 nm was 
also measured to detect nonspecific absorbance of the 96-well plate 
material. To obtain the relative IL-2 concentrations, absorbance 
values at 570 nm were subtracted from those at 450 nm. Data were 
analyzed using the software Prism.
Statistical analysis
Results were analyzed with GraphPad Prism 6. Statistics are based 
on two-way analysis of variance (ANOVA) and Bonferroni multiple 
comparison test. Each data point represents one of three indepen-
dent experiments, each performed in triplicate. The designations 
ns, *, ***, and **** denote P values for the measured differences of 
>0.05, ≤0.05, ≤0.001, and ≤0.0001, respectively (n = 3).
SUPPLEMENTARY MATERIALS
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Fig. S1. Autoinhibited conformation of SHP2.
Fig. S2. Interaction of the N-SH2 and C-SH2 domains with ITIM and ITSM.
Fig. S3. Lack of phosphorylation on ITIM and ITSM severely impairs their ability to bind both 
N-SH2 and C-SH2.
Fig. S4. NMR structure of the C-SH2–ITSM complex and overlay of unbound and 
phosphopeptide-bound structures of the SH2 domains.
Fig. S5. Overlay of the 1H-15N spectra of SHP21–220, SHP21–105, and SHP2110–220 in the bound and 
unbound forms.
Fig. S6. Small-angle scattering analysis of SHP21–220 and SHP21–525-C459S in the presence of 
the bidentate peptide.
Fig. S7. Superposition of the structures of N-SH2–ITIM and C-SH2–ITSM on the corresponding 
domains of SHP1 in the open state (PDB entry 3PS5) and SHP2-E76K in the open state (PDB 
entry 6CRF).
Fig. S8. CD69 expression levels of Raji B cells are not affected by coculture with Jurkat T cells.
Table S1. Crystallographic data collection and refinement statistics.
Table S2. NMR statistics for the structure of the C-SH2–ITSM complex.
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